Search Close


Investor Day Agenda

30th September 2013

Scancell Holdings Plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, is to host an Investor Update on Tuesday, 1 October 2013. Details of the event are:


FTI Consulting
Holborn Gate
26 Southampton Buildings
London, WC2A 1PB


Registration with refreshments


Introduction David Evans,

Scancell Non-Executive Chairman


Cancer immunotherapy

Prof Peter Stern, Head of the Immunology Group, Paterson Institute for Cancer Research, University of Manchester


Scancell corporate update

Dr Richard Goodfellow, Joint CEO of Scancell


SCIB1 trial update and introduction to Moditope™

Prof Lindy Durrant, Joint CEO of Scancell




Interactive panel discussion

Led by Prof Karol Sikora, Dean of Medicine , University of Buckingham; Honorary Consultant Oncologist at Hammersmith Hospital

Panellists include:

Prof Lindy Durrant,

Prof Peter Stern,

Dr Steve Chan, Consultant Oncologist, City Hospital, Nottingham University

and Prof Christian Ottensmeier, Dept. of Experimental Medicine, University of Southampton


Buffet lunch



For Further Information:

Scancell Holdings Plc


Dr Richard Goodfellow, Joint CEO

Professor Lindy Durrant, Joint CEO       

+ 44 (0) 20 7831 3113



Cenkos Securities:


Camilla Hume / Stephen Keys

+44 (0) 20 7397 8900



FTI Consulting


Mo Noonan / Eleanor Clarke

+44 (0) 20 7831 3113

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope™ technology platforms. Scancell’s first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is in Phase 1/2 clinical trials. Preliminary evidence from Part 1 of the study showing that SCIB1 produced an immune response which might be associated with clinical benefit in patients with malignant melanoma was released in December 2012.

Scancell’s ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 that destroy tumours without toxicity. The Directors believe that the Moditope™ platform could play a major role in the development of safe and effective cancer immunotherapies in the future.

Webcasts, Interviews and Media Coverage

New Scancell chief sets out his vision to commercialise groundbreaking cancer treatments

Cliff Holloway, chief executive of Scancell Holdings Plc (LON:SCLP), spoke to Proactive soon after taking over as CEO at the immuno-oncology company.

Holloway says generating clinical data's a big focus for them in the near-term.

''Over the next two years we expect to see clinical readouts from two of our programmes - SCIB1 and Modi-1''.

''We'll be extending our pipeline particularly around Moditope with the Modi-3 programme, if we're successful with the grand challenge''.

''Then it's around looking at technical partnerships that will allow us to de-risk our developments''.

Thu, 15 Feb 2018 12:38:00

Scancell to work with Dutch firm on first product for Moditope cancer immuno-therapy platform

Dutch group ISA Pharmaceutical will incorporate its Amplivant technology into Modi-1, the first cancer treatment candidate being developed on the platform

Thu, 15 Feb 2018 15:00:00

Scancell drug receives positive write-up in leading journal as company updates on survival data

Immuno-therapy SCIB1, which is expected to progress into Phase II clinical trials in the second-half of the year, was the focus of a peer-reviewed paper in OncoImmunology

Mon, 12 Feb 2018 11:50:00